What Is NAD+?

Overview

NAD+ (nicotinamide adenine dinucleotide) is not a peptide but a nucleotide-derived coenzyme found in every cell of the body. It cycles between an oxidized form (NAD+) and a reduced form (NADH), shuttling electrons through the chemical reactions that keep a cell powered. Beyond its classic role as a metabolic electron carrier, NAD+ is consumed as a substrate by several enzyme families that govern repair and signalling, which is why it has become a focal point in research on metabolism, mitochondrial health and biological aging. Tissue NAD+ levels are reported to fall with age and metabolic stress, though the extent and significance of that decline appears to vary considerably by tissue and context.

How NAD+ Works

In its electron-carrier role, NAD+ accepts a hydride to become NADH during glycolysis and the tricarboxylic acid cycle, then delivers those electrons to the mitochondrial electron transport chain to drive ATP synthesis. Separately, NAD+ is a consumable substrate for sirtuins (a class of NAD+-dependent deacetylases tied to stress-response and longevity pathways) and for PARP enzymes that perform ADP-ribosylation during DNA repair. The cellular NAD+ pool is therefore set by a balance between salvage and biosynthesis pathways and the activity of NAD+-consuming enzymes such as CD38 and the PARPs. Research models often raise NAD+ indirectly through precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — which feed the salvage pathway rather than supplying the intact coenzyme.

What the Research Explores

• Mitochondrial energy homeostasis and the partitioning of NAD+ between the nucleus and mitochondria.
• Oral precursor bioavailability — whether NR and NMN reliably elevate blood and tissue NAD+ markers.
• Skeletal-muscle NAD+ metabolome shifts and anti-inflammatory transcriptomic signatures in older adults.
• Insulin sensitivity and metabolic outcomes in selected populations, where human results remain mixed.
• Sirtuin and PARP signalling as links between NAD+ availability and cellular aging.

Forms & Handling

For research work, NAD+ is most often supplied as a lyophilized powder in 500 mg or 1000 mg vials. A 500 mg vial reconstituted with 3.0 mL of bacteriostatic water yields a concentration of 166.7 mg/mL; on a U-100 insulin syringe, a 100 mg measurement then corresponds to roughly 60 units (0.60 mL). Sealed lyophilized powder is best held at −20 °C or below, sealed and protected from light, while reconstituted solution is refrigerated at 2–8 °C and inspected for clarity before each draw. Note that oral precursor forms (NR, NMN) and any intravenous or injectable NAD+ preparations are handled very differently from this powder; see the dosing protocols below for the full reconstitution math in syringe units.

Safety & Research Notes

NAD+ in this context is an investigational research compound with no approved human or veterinary use and no established administration safety profile. A central caveat across the literature is that raising a NAD+ biomarker — for example, elevating blood NAD+ after supplementation — is not the same as demonstrating an improved clinical outcome; trials need to measure patient-relevant endpoints, not metabolite levels alone. Compounded injectable products are not pre-market reviewed for sterility, potency or quality, which adds a separate set of concerns. Everything described here is mechanistic and laboratory background, not a usage recommendation.

References

Related Protocols